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Background: Streptococcus pneumoniae (S. pneumoniae) causes several serious diseases including pneumonia,
septicemia and meningitis. The World Health Organization estimates that streptococcal pneumonia is the cause of
approximately 1.9 million deaths of children under five years of age each year. The large number of serotypes
underlying the disease spectrum, which would be reflected in the high production cost of a commercial vaccine
effective to protect against all of them and the higher level of amino acid sequence conservation as compared to
polysaccharide structure, has prompted us to attempt to use conserved proteins for the development of a simpler
vaccine. One of the most prominent proteins is pneumolysin (Ply), present in almost all the serotypes known at the
moment, which shows an effective protection against S. pneumoniae infections.
Results: We have cloned the pneumolysin gene from S. pneumoniae serotype 14 and studied the effects of eight
variables related to medium composition and induction conditions on the soluble expression of rPly in Escherichia
coli (E. coli) and a 28-4 factorial design was applied. Statistical analysis was carried out to compare the conditions
used to evaluate the expression of soluble pneumolysin; rPly activity was evaluated by hemolytic activity assay and
served as the main response to evaluate the proper protein expression and folding. The optimized conditions,
validated by the use of triplicates, include growth until an absorbance of 0.8 (measured at 600 nm) with 0.1 mM
IPTG during 4 h at 25°C in a 5 g/L yeast extract, 5 g/L tryptone, 10 g/L NaCl, 1 g/L glucose medium, with addition
of 30 μg/mL kanamycin.
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Conclusions: This experimental design methodology allowed the development of an adequate process condition
to attain high levels (250 mg/L) of soluble expression of functional rPly in E. coli, which should contribute to reduce
operational costs. It was possible to recover the protein in its active form with 75% homogeneity.
Keywords: Soluble expression, Experimental design, Design of experiment (DoE), rPly, Recombinant E. coli,
Hemolytic activityBackground
Streptococcus pneumoniae and pneumococcal diseases
Since it was first isolated in 1881, Streptococcus pneumo-
niae is one of the most extensively studied microorganisms.
In spite of the vast number of publications on the bacte-
rium, many questions about its pathogenicity are still un-
answered, and this pathogen remains a major causative
agent of serious human diseases such as pneumonia, menin-
gitis and bacteraemia [1]. Indeed, pneumonia is the leading
cause of child mortality worldwide, with 1.9 million of the es-
timated 10 million child deaths each year, with meningitis as
the second leading cause of child mortality. Additionally,
pneumococcus causes noninvasive diseases such as acute oti-
tis, sinusitis, conjunctivitis, and bronquitis. The incidence of
pneumococcal diseases is raising and is a serious global
problem. The vast majority of its victims come from the
poorest countries in the world [2].
Differences observed in the chemical composition and
also immunogenicity of the polysaccharide capsule (PS),
make it possible to recognize more than 90 different se-
rotypes of S. pneumoniae worldwide. Serotype preva-
lence may change based on patients age, geographical
region and type of infection [3]. S. pneumoniae expresses
a wide variety of surface proteins to interact with host
cell components during the colonization or dissemi-
nation stages of the bacterium. They are also involved in
the pathogenesis of the disease both as mediators of in-
flammation and as a direct part on host tissue attack [4].
Pneumococcal vaccines and pneumolysin as a potential
protein candidate for a new vaccine
Attempts to develop a vaccine to protect against the
pneumococcus based on capsular polysaccharides yielded
three licensed vaccines against S. pneumoniae which are
commercially available: Pneumovax (Merck), Prevnar or
Prevenar (Wyeth) and Synflorix (GSK). Pneumovax is a
23-valent PS vaccine with strong efficacy in adults but
poor efficacy in infants and young children (<2 years)
due to the lack of mature B cells. The other two avail-
able vaccines are based on PS conjugated to carrier
proteins to enhance the immunologic response, with a
broader efficacy in infants and young children, despite
the poor protection against less common serotypes. The
main disadvantages of these commercial vaccines are
the high-cost production process, and the incompletecoverage of serotypes whose incidence may vary among
countries [5,6].
Several pneumococcal proteins have been investigated
in the past two decades, as an alternative to the expen-
sive conjugate vaccines, as an antigen in potential
protein-based vaccine candidates or as carriers for poly-
saccharides, aiming to broaden serotype coverage with
less components in the vaccine [5-8]. In this regard, the
most interesting proteins described to date are the
pneumococcal toxin pneumolysin (Ply); choline-binding
surface protein family (CBPs); pneumococal surface pro-
teins, as the pneumococcal surface adhesin A (PsaA)
and pneumococcal surface protein A (PspA); and the
Caseinolytic protease (ClpP), among others under study.
These proteins are present in the majority of pneumo-
coccal serotypes isolated to date. Combinations of di-
verse pneumococcal proteins with conserved amino acid
sequences may provide the best serotype-independent
protection against S. pneumoniae.
Ply is a 471 amino acids monomeric protein with a
molecular mass of 53 kDa, folded in four globular do-
mains [9]. This protein shows a highly conserved 11 res-
idues sequence in one of the domains, rich in
tryptophan residues (ECTGLAWEWWR), suggested by
earlier studies [10,11] as the responsible sequence for
anchoring at host cell membrane and forming a trans-
membrane pore complex. Recent study by Soltani et al.
[12] suggested that the cholesterol recognition motif re-
sided within two structural loops, at the same domain
where the 11 residues sequence are located. The pores
upset the delicate osmotic balance between the cell and
its environment, allowing material to leak in and out
freely, quickly leading to lysis of the target cell [9,13,14].
Ply also presents other biological activities, depending
on the concentration, especially at the initial stage of the
pathogenesis of pneumococcal infection. In high concen-
trations, the enzyme is toxic to ciliated bronchial epithe-
lial cells, reducing the ciliary movement, destroying the
integrity of joints and cellular bronchial epithelial mono-
layer, facilitating the spread of pneumococcal infection.
It also interacts with the epithelial cells of the alveoli
and pulmonary endothelial cells, causing alveolar edema
and hemorrhage during pneumococcal pneumonia, and
easing the penetration from the epithelium to the pul-
monary interstitium and ultimately into the bloodstream
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hibit effector functions (respiratory bursts) of neutro-
phils and monocytes, chemotaxis, bactericidal activity,
and production of lymphokines and immunoglobulins
[14]. Consequently, the phagocytic activity of the host
cell is inhibited [9,15].
Optimization of heterologous protein production
In order to express target proteins in high yields, recombin-
ant DNA technology is the most appropriate tool and
Escherichia coli is one of the most used hosts, due to its
ability to grow rapidly at high cell density, with relative less
expensive substrates, in addition to its well-established gen-
etic background, and the existence of many commercial
cloning vectors and strains suitable for expression [16-18].
An improvement in the process of expression of recombin-
ant proteins can facilitate the subsequent step of purifica-
tion. Consequently, achieving high expression levels of
recombinant proteins is an essential step in the develop-
ment of a bioprocess, towards maximum profitability and
economic viability. However, there is no single, universal
process for the expression of all recombinant proteins in
this host, because the levels of expression of a heterologous
gene will depend on multiple variables that are specific to
each recombinant system. All these variables should be
carefully evaluated because they influence the system
[8,19].
The traditional method of process evaluation involves
varying one variable at a time, while keeping other variables
constant. This strategy requires a relatively large number of
experiments and frequently fails to anticipate optimal con-
ditions [20]. Changing one factor at a time does not depict
the combined effect of all the variables involved. It is also a
time consuming process because a large number of experi-
ments is required. The deficiency can be overcome by ap-
plying more efficient, statistic-based experimental design.
In this respect, factorial design is an important tool to de-
termine optimal process conditions. The advantage of using
the factorial design method is that many more variables can
be screened simultaneously and much quantitative infor-
mation can be extracted with a few experimental trials.
Statistical methods through factorial experimental designs
not only offer the simultaneous study of many variables,
but also allow the study of interactive effects of many fac-
tors together, facilitating the prediction of the response for
the values of variables not tested in the experiment [7,21].
In recent years, factorial designs - which are statistical tech-
niques for designing experiments, defined significant ef-
fects, building models, evaluating the effects of variables
and searching for optimum conditions - have successfully
been used to optimize many bioprocesses [22,23]; however,
they are not yet the most common strategies used to evalu-
ate heterologous protein expression. The use of statistically
designed experiments allows the rapid and economicaldetermination of optimal culture conditions with fewer ex-
periments and minimal resources [24]. Using a fraction of
the complete factorial design is also advantageous in cases
when the number of variables is larger than four, which de-
mands a great number of experiments. The fraction of ex-
periments should conserve the statistical condition of
orthogonality that allows the estimation of independent pa-
rameters [22,25].
In view of these considerations, the aim of this study
was to express recombinant Ply (rPly) in high concentra-
tions and in its soluble form, using E. coli as a heterol-
ogous expression system. To improve the protein
production, the many variables that influence the ex-
pression of this protein were evaluated, using experi-
mental design. As such, fractional factorial design was
used for eight variables related to medium composition
and induction conditions. These variables are the con-
centrations of yeast extract, tryptone, glucose, glycerol,
kanamycin, and inducer, the absorbance at induction
moment, and the temperature of expression after the in-
duction moment.
Results and discussion
Multivariant analysis and variables evaluated
The statistical experimental design methodology, where the
response is evaluated by changing more than one variable
at a time, allow the estimation of the variables that are sta-
tistically significant, taking into account the interactions
between them. This multivariant method permits a thor-
oughly analysis compared to the traditional univariant
method, where the response is evaluated changing one vari-
able at a time while fixing the others. Furthermore, the
multivariant method enables to characterize the experimen-
tal error, to compare the effects of variables between them-
selves when variables are normalized, and hence, to gather
high-quality information with as few experiments as
possible. All these advantages make this approach a power-
ful tool to optimize culture medium compositions and
process conditions for recombinant protein expression
[7,19,21,23,24,26-32].
When the recombinant protein is expressed intracellu-
larly in host cells, it is known that to yield high amounts
of that protein, it is necessary to achieve high cell
growth. Thus, the higher the cell growth, the more re-
combinant protein is synthesized [33]. As a conse-
quence, different operational strategies are developed to
increase cell growth. However, it is also known that pro-
tein may be expressed in a soluble or insoluble form,
into inclusion bodies. Several works in the literature
consider the formation of these inclusion bodies as a
drawback of the expression system in E. coli, because
they require further addition of a complex process of
isolation and purification, in which proteins are dena-
tured and refolded in vitro. Therefore, the recovery of
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subsequent stages of purification, making the global re-
covery low [34]. Thus, a major challenge in recombinant
expression is to design strategies for soluble production.
To evaluate whether the protein expressed in a soluble
form is directly related to cell growth, the first approach
of this study was to determine the variables that have
significant effects on cell growth and then compare that
effect pattern with the one obtained for the protein ex-
pression, which in turn was evaluated through the pneu-
molysin biological activity assay.
In order to define a process with high yields and re-
duced time for the expression of the recombinant pro-
tein pneumolysin in its soluble form, we assessed the
effects of eight variables related to medium composition
and induction conditions on three relevant responses
(cell growth, biological activity and productivity of rPly)
in bench scale. To that effect, a statistical strategy based
on a fractional factorial screening design was used, with
two levels for each of the eight variables (28-4) and rep-
licas at the central point. A previous study of this ex-
pression system reported that induction times longer
than 6 h were associated with lower productivity, mean-
while induction times between 4 h and 6 h presented
similar levels of productivity [35]. Thus, for this system,
the expression time was defined in 4 h, which means the
highest level of productivity of pneumolysin, for the low-
est operational time. A sequence of 24 different experi-
mental conditions was run to gather information about
these variables that may affect the rPly soluble expres-
sion. Results are presented in Table 1. When summiting
the E. coli BL21 Star (DE3)™ strain with pET plasmid
without the interest gene (negative control) to the same
expression process as the E. coli BL21 Star (DE3)™/
pET28a/ply, no band enhancement was detected in
SDS-PAGE analysis at the same size as rPly in the total
protein extract after 4 h induction, and no biological ac-
tivity was observed in the hemolytic assay.
Effect of variables on cell growth
After 4 h of induction, culture samples were taken to de-
termine cell growth, measured at an absorbance of
600 nm. As shown in Table 1, cell growth was different
among the 24 experimental runs, suggesting that certain
variables, related to medium composition and induction
conditions, have significant effects on that response. To
determine which variables those are, a statistical study of
the effects was carried out, considering significant effects
with p-value lower than 0.1, as shown in Table 2.
According to the statistical analysis (Table 2), six sta-
tistically significant variables could be recognized on the
cell growth, since they showed p-values lower than 0.1:
induction absorbance, inducer concentration, expression
temperature, concentrations of yeast extract, tryptone,and glucose. The two other variables, concentrations of
glycerol and kanamycin showed no significant effects.
When four variables were considered (induction absorb-
ance, expression temperature, and concentrations of
yeast extract and tryptone), it was possible to observe
positive effects on the response for higher values.
Based on the statistical analysis of cell growth, there
were only linear effects, since curvature was not signifi-
cant; that is, the highest cell growth could be achieved
by defining the significant variables at their extreme
levels depending on their positive or negative effects.
Cell concentration at induction is relevant, given the
fact that the expression of heterologous proteins may in-
hibit the growth because of the metabolic burden im-
plied in the expression process that restricts the energy
supply for other cell processes. During the stationary
phase, when cell growth reached its maximum, induc-
tion is not desired, since expression rate is proportional
to the growth rate at the induction moment. Therefore,
the best moment should happen when the metabolic ac-
tivity is completely active and consequently the growth
rate is peaking, which happens during the exponential
growth phase [36]. Based on these facts, expression in-
duction is done when culture is at the exponential phase,
but depending on the induction system and the recom-
binant protein, expression could be done at the initial,
intermediate or final part of that phase. For a high cell
growth, induction is better in the middle of the expo-
nential phase, according to the statistical evaluation.
In the case of inducer concentration, the effect on cell
growth was negative, showing a lower response value as
concentration is raised from the inferior to the superior
IPTG level. This phenomenon could be explained by the
toxic characteristic of IPTG, which is widely reported in
literature [31,37]. Noteworthy, expression of other re-
combinant proteins from S. pneumoniae studied in our
laboratory (PsaA and ClpP protease), using this same
host system, showed a negative effect of IPTG on cell
growth [7,31].
Another variable with negative effect on cell growth
was glucose concentration. This effect may be explained
because of the medium acidification by glucose metabo-
lization, which generates acidic by-products such as
acetic acid. Hansen et al. [38] showed a direct correl-
ation between acetic acid production and glucose con-
sumption when the medium contains glucose. In
contrast, when glucose was replaced for glycerol, no
acetic acid was detected in the supernatant. However, in
this study the only variable which was statistically sig-
nificant for medium pH change was glucose concentra-
tion; meanwhile glycerol did not presented statistical
effect.
On the other hand, a richer media in carbon source
(yeast extract and tryptone) and the temperature





[Yeast extract] [Tryptone] [Glucose] [Glycerol] [Kanamycin] Cell growth Hemolytic activity Process time (*) Productivity
Absind mM °C g/L g/L g/L % v/v μg/mL Abs HU/mL min HU/mL/min
1 0.8 (−1) 0.1 (−1) 25 (−1) 5.0 (−1) 0 (−1) 1 (−1) 0.0 (−1) 10 (−1) 2.08 612 345 1.77
2 2.0 (+1) 0.1 (−1) 25 (−1) 5.0 (−1) 0 (−1) 10 (+1) 0.4 (+1) 50 (+1) 2.86 1171 450 2.60
3 0.8 (−1) 1.0 (+1) 25 (−1) 5.0 (−1) 10 (+1) 1 (−1) 0.4 (+1) 50 (+1) 2.62 1306 345 3.79
4 2.0 (+1) 1.0 (+1) 25 (−1) 5.0 (−1) 10 (+1) 10 (+1) 0.0 (−1) 10 (−1) 3.46 1306 425 3.07
5 0.8 (−1) 0.1 (−1) 37 (+1) 5.0 (−1) 10 (+1) 10 (+1) 0.4 (+1) 10 (−1) 3.18 678 340 1.99
6 2.0 (+1) 0.1 (−1) 37 (+1) 5.0 (−1) 10 (+1) 1 (−1) 0.0 (−1) 50 (+1) 6.42 1188 385 3.09
7 0.8 (−1) 1.0 (+1) 37 (+1) 5.0 (−1) 0 (−1) 10 (+1) 0.0 (−1) 50 (+1) 2.78 658 350 1.88
8 2.0 (+1) 1.0 (+1) 37 (+1) 5.0 (−1) 0 (−1) 1 (−1) 0.4 (+1) 10 (−1) 3.76 656 470 1.40
9 0.8 (−1) 0.1 (−1) 25 (−1) 23.6 (+1) 10 (+1) 10 (+1) 0.0 (−1) 50 (+1) 3.45 1446 345 4.19
10 2.0 (+1) 0.1 (−1) 25 (−1) 23.6 (+1) 10 (+1) 1 (−1) 0.4 (+1) 10 (−1) 4.73 1344 403 3.34
11 0.8 (−1) 1.0 (+1) 25 (−1) 23.6 (+1) 0 (−1) 10 (+1) 0.4 (+1) 10 (−1) 2.65 915 345 2.65
12 2.0 (+1) 1.0 (+1) 25 (−1) 23.6 (+1) 0 (−1) 1 (−1) 0.0 (−1) 50 (+1) 4.21 1146 420 2.73
13 0.8 (−1) 0.1 (−1) 37 (+1) 23.6 (+1) 0 (−1) 1 (−1) 0.4 (+1) 50 (+1) 4.09 639 335 1.91
14 2.0 (+1) 0.1 (−1) 37 (+1) 23.6 (+1) 0 (−1) 10 (+1) 0.0 (−1) 10 (−1) 5.47 1013 420 2.41
15 0.8 (−1) 1.0 (+1) 37 (+1) 23.6 (+1) 10 (+1) 1 (−1) 0.0 (−1) 10 (−1) 4.02 335 335 1.00
16 2.0 (+1) 1.0 (+1) 37 (+1) 23.6 (+1) 10 (+1) 10 (+1) 0.4 (+1) 50 (+1) 5.40 1353 420 3.22
17 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.60 1469 370 3.97
18 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.79 1557 370 4.21
19 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.73 1610 360 4.47
20 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.82 1615 350 4.61
21 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.82 1506 370 4.07
22 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.68 1507 370 4.07
23 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.24 1158 370 3.13
24 1.4 (0) 0.55 (0) 31 (0) 14.3 (0) 5 (0) 5.5 (0) 0.2 (0) 30 (0) 3.32 1263 370 3.41

















Table 2 Effects of variables on cell growth, rPly activity and process productivity
Cell growth rPly activity Process productivity
Effect p-value Effect p-value Effect p-value
Mean/interc. 3.82 <0.0001 985.4 <0.0001 2.57 <0.0001
Induction absorbance 1.43 <0.0001 323.5 0.0016 0.33 0.2248
IPTG −0.42 0.0387 −52.0 0.5422 −0.19 0.4720
Expression temperature 1.13 <0.0001 −340.8 0.0011 −0.91 0.0041
Yeast extract 0.86 0.0004 77.0 0.3706 0.23 0.3930
Tryptone 0.67 0.0027 268.2 0.0061 0.79 0.0095
Glucose −0.33 0.0920 164.3 0.0685 0.37 0.1797
Glycerol −0.32 0.1011 44.8 0.5993 0.09 0.7241
Kanamycin 0.31 0.1163 256.0 0.0082 0.72 0.0160
Curvature −0.40 0.2356 950.5 <0.0001 2.85 <0.0001
In bold variables with statistical significance with a confidence level of 90% (p-value < 0.1).
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recombinant expression. Finally, kanamycin concentra-
tion showed no statistical effect on this response, as it
happened when it was evaluated in recombinant ClpP
protein expression [31].
Effect of the variables on the pneumolysin biological
activity and on process productivity
As it was previously discussed, heterologous protein ex-
pression in E. coli frequently happens in the cytoplasm.
Consequently, to obtain high levels of the foreign pro-
tein, a high cell growth culture is necessary [33]. How-
ever, recombinant protein expression in high cell growth
may happen in an insoluble and inactive way, forming
inclusion bodies. Thus, to express biologically active re-
combinant proteins, such as enzymes, it is necessary to
avoid inclusion bodies formation, which requires a thor-
ough study of the medium composition and the expres-
sion conditions of the system. Processes in which
protein was expressed in its active form were presented
by Nikerel et al. [26,39], and Volontè et al. [29]. Those
processes were optimized by using experimental design
strategy.
The main disadvantage of expressing a recombinant
protein in inclusion bodies is the high operational cost
for its recovery in a soluble way when it is needed
[33,40]. From an operational point of view, the import-
ance of a correct expression of a heterologous protein is
to go directly to the purification step, avoiding additional
previous steps, such as solubilization, oxidation, and re-
folding, during which a great amount of material is lost
[34].
In this study, the aim was to define a process to ex-
press rPly in its soluble form. As previously discussed, it
was necessary to evaluate the soluble fraction of pneu-
molysin, which is the active fraction, expressed in all 24
different operational conditions, to define the mostappropriate expression condition and then compare it
with the condition for the best cell growth to determine
whether the soluble rPly expression was correlated to
cell growth.
The soluble fraction of the protein was assessed by
measuring its hemolytic activity, since this is the only
way to measure the exact and correct structural folded
protein [41]. The statistical analysis of the effect of the
eight variables on the biological rPly activity is presented
in Table 2.
According to results in Table 2, five variables presented
statistically significant effects on rPly activity: induction ab-
sorbance, expression temperature, and the concentrations
of tryptone, glucose and kanamycin, since they presented
p-values lower than 0.1. The curvature was also statistically
significant, which means some responses do not have linear
behavior, consequently, the best response corresponds to
an intermediate value of the variable within the range
tested, in contrast with linear responses that were found at
the extreme levels of the range tested.
The negative effect of expression temperature was the
main effect on rPly activity, since it was the highest
value, and is in accordance with other studies, which
also observed that lower temperatures reduced the rate
of protein expression, thus avoiding the formation of in-
clusion bodies, enhancing soluble expression [28,29].
Volontè et al. [29] and Larentis et al. [7] showed that
there was growth rate reduction when expression
temperature was decreased from 37°C to 25°C, with a
concomitant enhancement in the soluble protein quan-
tity expressed. They also recognized that a lower reduc-
tion of the expression temperature implies an additional
cooling step, making it a more expensive process, be-
sides promoting significant reduction of cell growth. A
similar result was found by Swalley et al. [21], when they
studied medium composition and induction conditions
to express a viral protein in E. coli. However, depending
Marini et al. BMC Biotechnology 2014, 14:1 Page 7 of 13
http://www.biomedcentral.com/1472-6750/14/1on the protein, it may be adequate to reduce the
temperature to enhance the expression, and, conse-
quently, productivity [7].
Concerning the induction absorbance, to achieve high
amount of rPly in its soluble form, induction at high cell
concentration is preferable. The concentrations of tryptone
and glucose also had positive effect on rPly activity as well
as kanamycin concentration. This kanamycin effect can be
explained due to its contribution to the plasmid stability,
maintaining high concentration of plasmid bearing cells, fa-
voring the expression. At the lowest kanamycin concentra-
tion, probably, the plasmid segregation was drastically
higher than that at higher antibiotics concentration. Based
on a previous study carried out in our laboratory, it is
known that plasmid segregation occurs in the same pET
expression system for ClpP protease production, even at
the highest kanamycin concentration evaluated in this
study [31]. However, as the curvature is significant, and the
highest activity was observed at the central point, the best
condition to achieve a high activity could be defined at mid-
dle concentrations of these variables (tryptone, glucose and
kanamycin concentrations).
The other three variables, concentrations of IPTG, yeast
extract and glycerol, have no statistically significant effects
(p > 0.1). The lack of statistical effect leads these variables
to be defined at their lowest values to reduce operational
costs. Therefore, inducer concentration may be reduced
10-fold compared with the traditional IPTG concentration
used in most expression systems [26,29,34,36]. That is an
advantage because of its toxic effect on cell growth, as dis-
cussed before. This was also observed for the IPTG-based
expression of PsaA and ClpP proteins (within the 0.1 mM
to 1 mM range) in the same cell host studied in our la-
boratory [7,31]. Yeast extract concentration can be fixed
at 5 g/L, which is the lowest value normally used in most
studies [26,34]. Glycerol concentration was evaluated as a
glucose substitute to avoid acetate formation and to favor
protein stability [38], but it showed no beneficial effects
on rPly expression.
Comparing the patterns of the significant effects on
the cell growth and on the biological activity, we could
say there is no direct relationship between the solubility
of rPly and cell growth. Thus, to define the medium
composition and the induction conditions of a process
for the soluble expression of rPly, the activity is the main
response to be considered. However, the 24 different
processes presented a great variability in terms of
process times because they were induced at an absorb-
ance of 0.8, 1.4, and 2.0. Therefore, in order to avoid er-
roneous conclusions, the statistical analysis should be
done taking into account the biological activity regarding
the total process times, that is, the statistical analysis
should be done considering the different process pro-
ductivities, as it is shown in Table 2.The results presented in Table 2 show that expression
temperature was the main variable affecting productivity,
as observed on the biological activity analysis. The nega-
tive effect means the highest productivity level was
reached at lower temperatures within the range tested.
The concentrations of tryptone and kanamycin also sig-
nificantly affected process productivity, but in contrast
with the expression temperature, their effects were posi-
tive, which means that, for higher productivity levels,
these variables should be defined at higher levels. On the
optimization process for the rPsaA expression, tryptone
did not show statistical effect and thus could be possibly
removed from the medium [32]. Once more, the curva-
ture was also statistically significant, conferring a non-
linear effect to one or more variables. As curvature was
positive, productivity peaks within the evaluated range,
rather than at the extremes of that range. Therefore, to
define the best medium composition and induction con-
ditions, it is important to consider the productivity levels
at the central point, where the response presented the
highest level. In contrast, the other variables did not
have statistical effects on the process productivity. These
variables should be defined at their lowest levels within
the tested range, to reduce process costs as much as
possible without interfering on the productivity level of
the process.
Based on the previous discussion and on the factorial de-
sign analysis, it is possible to infer the more accurate condi-
tion which allows the maximization of system productivity.
Therefore, the medium composition was defined as follows:
5 g/L yeast extract, 5 g/L tryptone, 1 g/L glucose, 30 μg/mL
kanamycin, without glycerol, and with 10 g/L NaCl (vari-
able not evaluated in this factorial design). The expression
condition was defined by inducing the expression at ab-
sorbance of 0.8, with 0.1 mM IPTG, and allowing for 4 h
induction at 25°C.
The defined process showed that it is not necessary to
use a culture medium richer in yeast extract, tryptone, or
glucose, as most systems to express recombinant proteins
normally use. In this medium, yeast extract content can be
reduced about 5-fold compared to TB, a richer medium
used in E. coli cultures [32]. Tryptone and kanamycin can
also be reduced 2-fold in comparison to the highest con-
centrations tested, associated with TB and LB media con-
tent, and referred in Sambrook and Russell [42] molecular
cloning laboratory manual, respectively; inducer, which is
an expensive component, can be reduced 10-fold compared
with the standard concentration used to induce this kind of
system [42], and it is not necessary to add glycerol. Regard-
ing expression temperature, its reduction to 25°C leads to
energy saving, meanwhile induction at absorbance 0.8
means shorter process time.
The choice of tryptone and kanamycin concentration
levels was due to their significant and positive effects in
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were obtained when these variables were set at their
central levels. In addition, as the curvature was signifi-
cant and positive, both concentrations, statistically sig-
nificant, leading to a higher response when they are
defined at the central levels of the ranges tested. Once
the medium composition and induction conditions were
defined according to the statistical analysis on the prod-
uctivity of pneumolysin, the next step was to validate
that process.
Validation of the process defined by factorial design
Validation of the process defined by the factorial design was
carried out in triplicate during 4 h kinetics (k1, k2, k3). Cul-
tures in the medium grew at 37°C until reaching exponen-
tial growth phase (Absind 0.8), when they were induced with
0.1 mM IPTG and temperature was reduced at 25°C to ex-
press the recombinant pneumolysin. After that, cell culture
samples were taken every hour until the end of expression
process (4 h). These samples were used to evaluate cell
growth and productivity through process time. Results are
shown in Table 3.
The average of the pneumolysin activity in the validation
condition was 1394 ± 73 HU/mL, which is statistically the
same as the highest values obtained in the fractional design
experiments. The total process time was 310 min (growth
phase of 70 min and expression phase of 240 min), which
is the minimum process time obtained in the factorial ex-
periments. Thus, it can be observed that in this validated
process, in which most of the medium composition and in-
duction variables were defined at their lowest values, the
pneumolysin soluble expression was high even though the
medium composition was poorer and the total process time
was the shortest.
Figure 1 shows cell growth and the hemolytic activity of the
soluble fraction of the pneumolysin, through the total process
time. It is important to highlight that there was no hemolytic
activity detected in the strain E. coliBL21 Star (DE3)™/pET28a
culture (negative control), in the same culture and expressionTable 3 Cell growth and productivity for the validation
experiment
Induction time rPly activity Cell growth Yield per cell
h HU/mL Abs HU/mL/Abs
0* 0 0.82 ± 0.01 0
1 401 ± 18 1.60 ± 0.04 251 ± 7
2 656 ± 62 2.42 ± 0.09 272 ± 33
3 867 ± 20 2.65 ± 0.02 328 ± 6
4 1394 ± 73 2.93 ± 0.17 476 ± 34
Results are averages of three experiments. Expression of rPly was performed at
Absind 0.8 with 0.1 mM IPTG for 4 h induction at 25°C in a medium culture
comprised of 5 g/L yeast extract, 5 g/L tryptone, 1 g/L glucose, 30 μg/mL
kanamycin and 10 g/L NaCl.
*Induction moment.conditions of the strain E. coliBL21 Star (DE3)™/pET28a/ply.
Thus, the hemolytic activity is related to the recombinant
protein pneumolysin.
The cell growth kinetic show that after a two-hour in-
duction (190 minutes of process), the cells started to
reach the stationary growth phase, while the rPly activity
was still rising. As discussed above, the pneumolysin ex-
pression, measured through its hemolytic activity, is not
directly associated with cell growth, which can be con-
firmed in this kinetics (Figure 1). Based on the literature,
this might happen due to the use of systems with strong
promoters, such as T7 promoter. This kind of promoter,
during induction, makes the cell energy turn to the pro-
tein expression to the detriment of cell growth, conse-
quently the growth rate drops because the host cell
metabolism is overburdened [31,43]. The specific growth
rate obtained in this study was 0.56 h-1. Possible differ-
ences with other recombinant E. coli may be related to
the different gene expressed, the interaction host/vector
as well as the properties of the expressed protein [34,40].
The productivity average obtained in the validated
process defined from the statistical fractional design was
4.50 HU/mL/min, with a standard deviation of 0.24 and a
relative standard deviation of 5.3%. Comparing this value
with the ones of the fractional design experiments, it is sta-
tistically equivalent to those obtained in experiment 9
(4.19 HU/mL/min), as well as those experiments performed
at the central point (3.99 ± 0.50 HU/mL/min). These values
are the highest productivity values obtained among the
values from design experiments. That is relevant since
highest rPly productivity levels were noticed in a relative
low-cost and time-consumption.
Preliminary purification process
The characteristics of recombinant protein production,
the molecule location, and protein destination determine
its purification process. Within the biopharmaceutical
production processes, purification accounts for a high
part of product cost, because it often results in low re-
covery of protein.
In this work, the soluble fraction of rPly expressed in
E. coli at 25ºC was used at the preliminary purification
tests. The expression of rPly in total extract, soluble and
insoluble fractions are presented in Figure 2. The densi-
tometry analysis of the rPly band performed on the
SDS-PAGE indicated that this protein is expressed
around 250 mg/L, which corresponded to 25-28% of the
total E. coli protein extract. The soluble fraction of rPly
was around 90% from the total of rPly expressed in this
condition.
Recombinant protein purification was conducted using
two different strategies, ion exchange and affinity chro-
matography, without fusion tags. These strategies were















































Time of culture (min)
Figure 1 Cell Growth (●) and rPly Activity (▲) through the total process. Arrow is indicating the induction moment. Standard deviation of
triplicate runs.
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recovery of a 75% homogeneity rPly fraction (shown in
SDS-PAGE). Considering there are not many works in
literature performing purification of rPly, and to our know-
ledge, neither Q FF column nor Thiopropyl Sepharose
column were tested for this protein, these preliminary
results could be considered as prominent. However,
both methods need to be optimized in order to enhance
recovery yields, as well as homogeneity, and to develop
a feasible purification method that could be used in aFigure 2 SDS-PAGE of rPly expression and preliminary purification. N
4 h induction (total protein extract, soluble and insoluble fractions). Prelimi
Q FF column and 7-8 mM DTT elution using Thiopropyl matrix (MW =moleproduction process of rPly. Hemolytic activity of the
protein was confirmed after both processes, which was
maintained after 8 days stored at 4ºC. These results for
one-step purification of rPly without tags were compar-
able to those homogeneities described in the literature
for several purification steps [44], and allowed the pro-
duction of the recombinant protein with conformation
closer to the original fold [7]. One of the major advan-
tages of our cloning strategy without tags for purifica-
tion is its ability to produce a protein which is ready toon-induced sample and rPly expression at 25°C in TB medium after
nary purification fractions obtained with 30% NaCl elution using
cular weight).
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the tag removal step after purification, which is a step
that increases process costs.
Conclusions
Different levels of a soluble form of recombinant pneu-
molysin were obtained in all the experiments of the frac-
tional design used. As there was no direct relationship
between cell growth and soluble rPly expressed, and as
total process time varied in the different levels of ab-
sorbance at induction, biological activity was the main
response to be considered to find out the variables with
statistically significant effects on productivity. The tem-
perature of expression and the concentrations of tryp-
tone and kanamycin were the three variables which
affected productivity. The defined process was success-
fully validated, which yielded 4.50 HU/mL/min, one of
the highest productivity values obtained compared with
the productivities of the experimental design and with
reduced operational costs. It should, therefore, be pos-
sible to reduce the inducer concentration ten-fold, re-
duce absorbance time of the induction moment and the
concentrations of yeast extract, glucose, and glycerol to
the minimum levels of the ranges tested, keeping rPly
protein expression at high levels (250 mg/L, which cor-
responded to 25-28% of the total E. coli protein extract)
and reducing process costs.
Once more, and in accordance with different literature
data, the results presented emphasize the importance of
experimental design to improve the biotechnological
conditions of processes used to express a recombinant
protein in E. coli. It was also proven it is necessary to
have a minimum number of experiments to gather rele-
vant information on the effect of each of the variables
under study, as well as the experimental error. In con-
trast with traditional univariant methods, the assessment
of various variables at the same time avoids the lack of
considerations about the interactions of the relevant ef-
fects. All these advantages make experimental design a
powerful tool for defining an optimized recombinant
protein production process.
The reduction in the production cost of this protein - as
well as other potential target proteins used in a possible
protein-based vaccine, through the use of experimental
design - demonstrated how essential this statistical tool is
to obtain a highly efficient commercial vaccine with low-




Bacto™ yeast extract and tryptone were purchased from
BD (Becton, Dickinson and Company), glucose and NaCl
were purchased from Merck, glycerol from Invitrogen,kanamycin from Sigma and IPTG (isopropyl β-D-1-thio-
galactopyranoside) was purchased from Promega. Potas-
sium salts (K2HPO4 and KH2PO4) used in the medium
were purchased from Merck.
Cloning procedure
The Escherichia coli BL21 Star (DE3)™ strain (Invitrogen)
was used as a host for the plasmid pET28a (Novagen)
harboring the gene responsible for pneumolysin expres-
sion, and kanamycin resistance. Pneumolysin protein-
coding gene was isolated from S. pneumoniae serotype
14, since it is the most prevalent in Brazil and also one
of the most prevalent and virulent serotype in the world.
The clone expressing the recombinant protein pneumo-
lysin was developed at LATER/Bio-Manguinhos/FIO-
CRUZ and cloning techniques were reported in Larentis
et al. [7] and Einsfeldt et al. [31]. The clone cryo-
preservation was at -70°C in 25% glycerol (Invitrogen).
The working vials of the clone E. coli BL21 Star (DE3)™/
pET28a/ply, thawed from the working bank, were evalu-
ated in reference to their cell viability.
Cell viability test
The cell viability of the working vials of recombinant
E. coli BL21 Star (DE3)™/pET28a/ply in LB (5 g/L yeast
extract, 10 g/L tryptone, 5 g/L NaCl, pH 7.0) with 25%
glycerol, stored at -70°C, was assessed by counting the
colony forming units (CFU) for all the experimental de-
sign experiments. Serial dilutions were made in PBS
pH 7.4 and transferred to Petri plates containing LB Agar
and 50 μg/mL kanamycin (concentration of working vials
were, on average, 28×1010 CFU/mL).
Variables and experimental design
Eight variables of the expression process, related to both
the composition of the culture medium and the in-
duction conditions, were chosen to be evaluated by the
experimental design: concentrations of yeast extract, tryp-
tone, glucose, glycerol, kanamycin and inducer, absorb-
ance at induction moment, and expression temperature
(Table 4).
To evaluate the statistical effects of the variables on
the soluble expression of pneumolysin, a fractional fac-
torial design 28-4 was chosen, with replicates on the cen-
tral point. This fractional factorial design is resolution
IV, which means that the main effects can be deter-
mined, but not their interactions [22]. The curvature
was also evaluated by the factorial design, which allowed
us to learn whether effects are linear or not. When a
variable effect is linear, the highest response is obtained
at the highest level of the variable for a positive effect, or
at the lowest level for a negative effect. On the other
hand, when a variable effect is not linear, the highest or








Induction absorbance (Absind) 0.8 1.4 2.0
IPTG (mM) 0.1 0.55 1.0
Expression temperature (°C) 25 31 37
Yeast extract (g/L) 5 14.3 23.6
Tryptone (g/L) 0 5 10
Glucose (g/L) 1 5.5 10
Glycerol (%v/v) 0 0.2 0.4
Kanamycin (μg/mL) 10 30 50
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mediate level of the variable within the range evaluated.
Due to the large variability inherent to bioprocesses,
the parameters were considered significant with p-values
lower than 10% (p < 0.1). Using 90% confidence in the
statistical analysis (Software Statistica 9.1/Statsoft) al-
lowed the inclusion of possible relevant variables that
would be excluded from a strict statistical analysis with
a significance level of 5% (p < 0.05). The normalization
of the levels of each variable allows the comparison of
the importance of each variable effect, in reference to
the evaluated response. Once the most adequate experi-
mental design was chosen, the next step was to select
the range of values to be studied for each of the eight
variables, defining the lowest level as −1, the highest
level as +1, and 0 as the central point calculated as the
middle of these two levels (Table 4). IPTG and kanamy-
cin levels were defined based on information found in
literature [35,42]; induction conditions and media com-
position were chosen according to previous studies with
pneumolysin [35] and other S. pneumoniae proteins
expressed in E. coli [7,31,32]; temperature levels were se-
lected evaluating rPly solubility [35]; induction absor-
bances were defined at the initial (absorbance 0.8
measured at 600 nm) and at the middle (absorbances 1.4
and 2.0) exponential phase from cell growth kinetics in
different medium compositions and temperatures [35];
media components levels were chosen based on LB
(Luria-Bertani) and TB (Terrific Broth) media composi-
tions [32,35].
Protein expression and purification process
Recombinant E. coli BL21 Star (DE3)™/pET28a/ply was
pre-inoculated (10 μL of working vial) in 10 mL of the
TB medium (23.6 g/L yeast extract, 11.8 g/L tryptone,
9.4 g/L K2HPO4, 2.2 g/L KH2PO4, pH 7.2) enriched with
1% glucose, 0.4% glycerol and 50 μg/mL kanamycin. Thepre-inoculum was incubated for 16 hours at 37°C and
200 rpm in 50 mL flasks under agitation; simultaneously,
the cell viability test was done. After 16 h, the 24 differ-
ent expression experiments were done in 6 different sets
of experiments and in each group a central point repeti-
tion was performed, as discussed below. The inoculum
was prepared in 500 mL flasks with 2 mL pre-inoculum
and 100 mL of the medium, with the corresponding
yeast extract, tryptone, glucose, glycerol, and kanamycin
concentrations, according to the experimental design (as
described in the previous section). The culture was incu-
bated at 37°C and 200 rpm until it reached the evaluated
values of the exponential growth phase. At this point,
expression was induced with the corresponding IPTG
concentration for four hours under different expression
temperature, as the experimental design indicated. In
addition to the 16 different expression conditions, 8 rep-
licates of the central point were done to define the ex-
perimental error associated to this kind of expression
process, as well as the curvature, resulting in the 24 dif-
ferent runs. Samples of 1 mL volume were taken from
each experiment before and after the four-hour expres-
sion period to assess cell growth and soluble rPly expres-
sion (by hemolytic activity).
The same expression process was done using an
E. coli BL21 Star (DE3)™ strain, with the pET28a plasmid
without the interest gene, as a negative control, to confirm
the lack of expression of rPly in a SDS-PAGE analysis
and also the lack of biological activity in an hemolytic
analysis.
The recombinant protein was purified in an ÄKTA
Purifier 10 system by strong anion exchange in a 1 mL
Q FF column (Hitrap Q Sepharose™ Fast Flow/GE
Healthcare) with 50-100 mM NaCl added to the initial
sample and eluted with 20 mM Tris HCl and 300 mM
NaCl (pH 8.0). Purification was also tested by affinity
using a Thiopropyl Sepharose™ 6B matrix (GE Health-
care) that reacts with solutes containing thiol groups,
and elutes using the same elution buffer with 5-25 mM
DTT.
Samples were analyzed by 12.5% SDS-PAGE stained
with Coomassie blue and densitometry was used to
evaluate the concentration related to the rPly band in
the total protein extract, soluble and insoluble (inclusion
bodies) fractions and also to evaluate the homogeneity
of purification fractions in a Bio-Rad GS-800 Calibrated
Densitometer/QuantiOne 4.4.1 software according to
Larentis et al. [7].
rPly solubility by hemolytic activity measurements
The cells from the pre-induction (0 h) and after 4 h induc-
tion samples were harvested by centrifugation at 20817 × g
for 10 min at 4°C to separate the culture medium. In order
to solubilize the expressed rPly, the cells were resuspended
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pH 8.0) restituting the 1 mL sample volume, to obtain the
total protein extract. The total extract was disrupted by eight
10-second ultrasound cycles at 60% amplitude in an ultra-
sonic cell disruptor (Sonics & Materials, Inc.). The soluble
and insoluble protein fractions were separated from the cul-
tures by centrifugation (20817 g for 10 min at 4°C). The
soluble fraction was used to assess the hemolytic activity.
In round-bottomed 96-well microplates, a two-fold
serial dilution was done with 100 μL of soluble fraction
from each experimental condition using the lysis buffer
(20 mM Tris, 1 mM EDTA, 200 mM NaCl, pH 8.0). A
volume of 100 μL of triple-washed 2% defibrinated bo-
vine blood cells in the same lysis buffer was added to the
dilutions and incubated for 1 h at 37°C and overnight at
4°C, so as to allow unlysed red blood cells to sink to the
bottom of the well and form a clear red dot in the trans-
parent solution. On the other hand, lysed cells release
their hemoglobin, giving the solution a red color that al-
lows the monitoring of protein lysing activity. A volume
of 100 μL supernatant from each well was transferred to
a new flat-bottomed 96-well microplate. The hemolytic
activity was evaluated spectrophotometrically at 540 nm
by assaying the hemoglobin released in the supernatant.
Samples with 2% blood cells completely lysed as a 100%
lysis reference were serially two-fold diluted in lysis buf-
fer to produce the standard curve; the supernatant of 2%
erythrocyte suspension (100 μL) incubated with lysis
buffer was used as the blank reference (0% lysis). One
Hemolytic Unit (HU) was expressed as the quantity of
rPly presented in a sample comparing with the standard
curve, which allows the obtainment of complete
hemolysis of a 2% erythrocyte suspension, after 1 h incu-
bation at 37°C. Therefore, the first well of the standard
curve contained 1 HU. That hemolytic activity was re-
lated to 1 mL of sample.
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